Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Benzinga

Can new COVID-19 vaccine win over the anti-vaxxers?

With three COVID-19 vaccines already authorized by the U.S. Food and Drug Administration, Americans have easy access to plenty of shots.

Tribune News Service

FDA advisers back Novavax COVID-19 shots as new US option

A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

MTG falls for fake Twitter account

The fake account misleadingly tweeted that Pfizer's vaccine has caused widespread miscarriages

Salon

Morning Brief: Top Financial Stories Dominating on Tuesday, June 7

Reuters

Benzinga

Pfizer To Boost Production Of Oral COVID-19 Pill With $120M Michigan Investment

Pfizer, Inc. (NYSE: PFE) is upping its commitment to manufacture its oral COVID-19 pill Paxlovid in the United States.

Benzinga

Novavax's new shot may sway anti-vaxxers

Experts hope the new COVID vaccine, which uses older biotechnology, could help the unvaccinated come around

Salon

Read news from The Economist, FT, and more,
with one subscription

Numbers ploy

Re: "Toxically un-Thai," (letters, June 1).

Bangkok Post

Kids under 5 should soon have access to COVID vaccines, but many parents are likely to say, I don’t feel comfortable'

PHILADELPHIA — Zoli’s parents plan to get their 4-year-old son vaccinated against COVID-19 as soon as shots for young children could finally become available later this month.

The Philadelphia Inquirer

We still need a vaccine patent waiver, but not the one on offer at the World Trade Organization meeting

In mid-June, the World Trade Organization (WTO) will meet to finish negotiations to waive certain sections of the agreement on Trade Related Intellectual Property Rights (TRIPS). However, it is not the TRIPS waiver originally proposed 18 months ago by member states South Africa and India, which would have allowed countries…

The Conversation

US FDA Concerned over Potential Novavax Myocarditis Risk

The Food and Drug Administration voiced concern Friday about myocarditis being potentially linked to the Novavax Covid-19 vaccine, just as experts are to weigh its use in the United States. The Novavax vaccine is already authorized in other countries, particularly in Europe. In the United States, an independent committee convened…

Asharq Al-Awsat

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Social media spreads rumours about COVID vaccine harms, but it doesn't always start them

For decades, anti-vaccine movements have generated and spread rumours that vaccines cause serious health problems. The rollout of COVID vaccines has provided new opportunities to spread misinformation.

The Conversation

COVID vaccines for children under 5 possible by June 21, White House says

The FDA and CDC will still need to authorize the shots.

Axios

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Novavax hopes its COVID shot wins over FDA, vaccine holdouts

Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine

Wales Online

Covid vaccines for the under-fives - what parents need to know

Children under five represent the only age group yet to have a vaccine approved for use

Benzinga

FDA Accepts Myovant Sciences and Pfizer's Filing For Review In Uterine Fibroids

Myovant Sciences (NASDAQ: MYOV) and Pfizer (NASDAQ: PFE) received U.S.

Benzinga

Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five

Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results…

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

‘We’re playing with fire’: US COVID cases may be 30 times higher than reported

Severe undercounting undermines our efforts to ‘understand and get ahead of the virus’, researcher says after New York survey

Tribune News Service

Pfizer submits COVID-19 shot for children under 5 for FDA authorization

WASHINGTON — Pfizer Inc. asked U.S. regulators to clear its COVID-19 vaccine for emergency use in children under age 5, an effort to extend protection against the virus to the country’s youngest.

The Conversation

COVID vaccines for children under five: what parents need to know

Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021.

Benzinga

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

Close on the heels of an M&A deal, GlaxoSmithKline plc (NYSE: GSK) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. pharma giant Pfizer, Inc.

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, June 1

Reuters Redbird Capital Buys Italian Football Club AC Milan

Benzinga

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

Reuters

U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.

1 … 51 52 53 54

People

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations